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Abstract
Aims: The aim of this study was to evaluate and compare lesion dimensions and thermodynamics of the 
new-generation multi-electrode Symplicity Spyral and the new-generation multi-electrode EnligHTN renal 
artery denervation systems, using a thermochromic liquid crystal phantom model.
Methods and results: A previously described renal artery phantom model was used as a platform for 
radiofrequency ablation. A total of 32 radiofrequency ablations were performed using the multi-electrode 
Symplicity Spyral (n=16) and the new-generation EnligHTN systems (n=16). Both systems were used as 
clinically recommended by their respective manufacturer. Lesion borders were defined by the 51°C iso-
therm. Lesion size (depth and width) was measured and compared between the two systems. Mean lesion 
depth was 2.15±0.02 mm for the Symplicity Spyral and 2.32±0.02 mm for the new-generation EnligHTN 
(p-value <0.001). Mean lesion width was 3.64±0.08 mm and 3.59±0.05 mm (p-value=0.61) for the 
Symplicity Spyral and the new-generation EnligHTN, respectively.
Conclusions: The new-generation EnligHTN system produced lesions of greater depth compared to the 
Symplicity Spyral under the same experimental conditions. Lesion width was similar between both sys-
tems. Achieving greater lesion depth by use of the new-generation EnligHTN may result in better efficacy 
of renal artery denervation.
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Abbreviations
BP blood pressure
RAD renal artery denervation
RF radiofrequency
TLC thermochromic liquid crystal
SS Symplicity Spyral
NGE new-generation EnligHTN
Introduction
Following the encouraging results of the Symplicity HTN-1 and 
Symplicity HTN-2 trials, which demonstrated significant blood 
pressure (BP) reduction after renal artery denervation (RAD), 
endovascular radiofrequency (RF) ablation of the renal arter-
ies was considered an acceptable treatment for drug refractory 
hypertension1,2. Later, the randomised controlled SYMPLICITY 
HTN-3 trial failed to show a significant difference in BP reduc-
tion between the RAD treatment arm and the sham control arm3. 
Nevertheless, the implication of renal sympathetic nerves in the 
pathogenesis of resistant hypertension has been well described 
and demonstrated in previous animal and human studies4-8. Several 
factors have been proposed that may have limited the denervation 
efficacy in SYMPLICITY HTN-39. A better understanding of the 
basic mechanisms of denervation and factors affecting procedural 
success including patient selection, renal nerve anatomy and the 
biophysics of the various renal denervation systems through fur-
ther preclinical studies is pivotal to achieving the desired results.
Previously, we developed a thermochromic liquid crystal 
(TLC) model and validated it in vivo for cardiac RF ablation10. 
Subsequently, we modified this model for renal denervation. In 
our previous study, we assessed and compared lesion size and 
thermodynamic properties of the single-electrode Symplicity 
(Flex) renal denervation system (Medtronic, Minneapolis, MN, 
USA) versus the first-generation multi-electrode EnligHTN sys-
tem (St. Jude Medical, St. Paul, MN, USA) using the TLC renal 
artery phantom model11. Recently, in the new-generation systems, 
several modifications have been applied to both the EnligHTN and 
Symplicity renal denervation systems in order to overcome some 
of the technical procedural challenges, and to reduce overall pro-
cedural duration, either of which could ultimately impact on abla-
tion efficacy. Therefore, in this study we aimed to evaluate and 
assess the performance of the new-generation Symplicity Spyral 
(SS) and the new-generation EnligHTN (NGE) renal denervation 
systems using the previously described renal artery phantom 
model. Table 1 summarises the differences between the old and 
the new Symplicity and EnligHTN systems.
Methods
Radiofrequency ablations for both the SS and NGE systems were per-
formed in the renal artery phantom model using clinically recommended 
ablation settings (Table 1). Temporal changes in lesion dimensions 
(depth and width) for the two systems were measured and compared.
THERMOCHROMIC LIQUID CRYSTAL PHANTOM RENAL 
ARTERY MODEL
The renal artery phantom model was prepared as previously 
described11. In summary, a mixture of saline and an agar substi-
tute powder (Phytagel™; Sigma-Aldrich [now Merck], St. Louis, 
MO, USA) was heated to 90°C in a preformed cast encompassing 
a 5 mm diameter cylindrical former. Once cooled, the former was 
removed to create a transparent block of gel with a 5 mm diameter 
lumen to simulate the renal artery. A TLC film that has tempera-
ture sensitivity between 50-78°C (Hallcrest LCR, Connah’s Quay, 
United Kingdom) was embedded within the gel prior to solidifi-
cation. The gel block was placed in a tank, which pumped saline 
around the gel and into the phantom renal artery lumen at a rate of 
500 ml/min and a temperature of 37°C.
RADIOFREQUENCY ABLATION
The ablation catheter for the system was introduced into the phan-
tom renal artery under direct visualisation. The Spyral catheter was 
advanced into the phantom lumen over a (0.014-inch) guidewire 
as clinically recommended. Once within the lumen of the phantom 
renal artery, the guidewire was pulled back to allow spiral configu-
ration of the catheter. In the case of the EnligHTN catheter, a small 
diameter basket size (recommended for vessel diameters between 
4 and 6 mm) was used and the catheter was deployed on a sin-
gle instance per gel to limit abrasion of the gel surface. At least 
one electrode was positioned in plane with the TLC sheet. Only the 
electrode in contact with the TLC sheet was activated for each RF 
ablation (one electrode per run). All ablations were performed with 
Table 1. Summary of the technical specifications and a comparison between the new and old Symplicity and EnligHTN renal denervation 
systems.
System
Old systems New systems
Symplicity (Flex) EnligHTN old generation Symplicity (Spyral) EnligHTN new generation
Generator Symplicity G2 1st generation Symplicity G3 2nd generation
Number of electrodes 1 4 4 4
Ablation duration (sec) 120 90 60 60
Maximum power per electrode (W) 8 6 6.5 8
Electrode surface area (mm2)* 6.39 3.7 5.9 3.7
* Measured in-house.
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a flow rate of 500 ml/min through the phantom renal artery, and an 
ablation duration of 60 sec. The gel was allowed to cool down for 
five minutes between RF ablations and the catheter was moved to 
a new position after four runs of ablation.
LESION MEASUREMENTS AND ANALYSIS
A digital camera (Canon EOS 5D Mark II; Canon Inc., Tokyo, 
Japan) with a light source (Canon Speedlite 580EX; Canon) was 
placed in front of the phantom model to capture images at dif-
ferent ablation time points (at baseline, 20 sec, 30 sec, 40 sec, 
50 sec and 60 sec). Heating of the gel at the TLC surface pro-
duced a colour gradient on the TLC sheet (Figure 1A), which was 
utilised to calculate the isotherms following thermochromic cali-
bration using in-house developed software (Figure 1B). The 51°C 
isotherm was used as an arbitrary measure to define lesion bor-
ders, as irreversible neural tissue injury occurs at temperatures 
greater than 45-50°C12,13. Lesion depth (d) was measured as the 
length of a line between the electrode/gel interface and the 51°C 
isotherm perpendicular to the electrode tip. Lesion width (w) was 
defined as the maximum width of the 51°C isotherm perpendicular 
to d (Figure 1B).
STATISTICAL ANALYSIS
Based on previous work in the same phantom model, RF ablation 
in replicates of three per catheter were required to detect a signi-
ficant difference in lesion size, with a power of 95% and α=0.05 
(two-tailed), for each parameter tested11. Mean lesion depth and 
width for each system were compared using an unpaired two-tailed 
Student’s t-test. Data were expressed as mean±standard deviation. 
The relationship between lesion growth (depth and width) and 
time was assessed using Spearman’s correlation. Values of p<0.05 
were considered significant. Data analysis was performed with 
GraphPad Prism software 6.0 (GraphPad Software Inc., La Jolla, 
CA, USA) and SPSS, Version 24 (IBM Corp., Armonk, NY, USA).
Results
A total of 32 RF ablations (16 ablations per system) were per-
formed on the phantom renal artery model. All ablations were car-
ried out under similar phantom conditions whereby parameters, 
including phantom vessel diameter, flow rate and gel temperature, 
were adjusted to within normal physiological ranges of 5 mm, 
500 ml/min and 37°C, respectively. Table 2 summarises the abla-
tion parameters for both systems. 
LESION SIZE AND GROWTH
Thirty-one RF ablation lesions (16 for SS and 15 for NGE) were 
analysed at 60 sec to determine final lesion size. A single data 
point for the NGE group was unavailable due to photographic 
aberration. Immediately prior to termination of RF ablation 
(60 sec), mean lesion depth for SS was 2.15±0.02 mm versus 
2.32±0.02 mm for NGE (p-value <0.001) (Figure 2A). Mean lesion 
width was 3.64±0.08 mm and 3.59±0.04 mm (p-value=0.61) for 
SS and NGE, respectively (Figure 2B).
In addition, temporal analysis of lesion dimensions was per-
formed to demonstrate the thermodynamics of each ablation system 
(Figure 3). A Spearman correlation test demonstrated a strong positive 
correlation between the duration of RF ablation and lesion size (depth 
and width), which was statistically significant for both systems. The 
correlation coefficient (rs) for ablation duration versus lesion depth 
was 0.91 (p<0.001) for SS and 0.86 (p<0.001) for NGE. The corre-
lation coefficient (rs) for ablation duration versus lesion width was 
0.606 (p<0.001) and 0.726 (p<0.001) for SS and NGE, respectively. 
Figure 1. Image taken during radiofrequency ablation on the 
phantom renal artery model at 60 sec using the Symplicity Spyral 
system in this case. A) Colour gradient on the TLC sheet during RF 
ablation. B) Lesion post analysis with superimposed isotherms. 
Yellow line highlights the 51°C isotherm. C) Colour gradient with 
the corresponding temperature in °C. d: lesion depth; w: lesion 
width; TLC: thermochromic liquid crystal
Table 2. Ablation parameters for Symplicity Spyral and new-
generation EnligHTN systems.
System
Symplicity 
Spyral
New-generation 
EnligHTN
p-value
Ablation number 16 16 –
Mean power (V) 6.5±0.00 
(maximum power)
5.3±0.07 
(average power)
–
Mean baseline 
impedance (Ω) 174.3±0.88 199.1±0.88 <0.001
Mean electrode tip 
temperature (°C )
45.56±0.66 
(maximum 
temperature)
52.50±0.98 
(average 
temperature)
–
Ablation duration (sec) 60 60 –
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Figure 2. Scatter plots comparing lesion depth and width for the 
Symplicity Spyral and new-generation EnligHTN sytems at end of 
radiofrequency ablation (60 sec). A) Lesion depth. B) Lesion width. 
NGE: new-generation EnligHTN; SS: Symplicity Spyral
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The current RAD systems
Graphs of lesion depth and width over time (Figure 3) suggest that 
prolonging the ablation duration could potentially increase lesion 
size, as a plateau phase has not been reached. Nonetheless, analy-
sis of lesion size at different ablation time points demonstrated that 
about 70-80% of lesion growth occurred within the first 20 sec of 
RF delivery with a lesion growth rate of 0.076 mm/sec for depth and 
0.147 mm/sec for width with SS, and 0.094 mm/sec for depth and 
0.124 mm/sec for width with NGE during the initial 20 sec abla-
tion phase. Lesion growth rate slows down thereafter to 0.012 mm/
sec for depth and 0.01 mm/sec for width with SS and 0.009 mm/sec 
for depth and 0.008 mm/sec for width with NGE in the last 20 sec 
of RF ablation. Thus, increasing ablation time beyond 60 sec may 
result in only a small increase in lesion size. Table 3 summarises 
lesion dimensions at 20, 40 and 60 seconds of RF ablation and the 
percentage of lesion growth (depth and width) at each time point.
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Figure 3. Graph demonstrating the relationship between 
radiofrequency ablation duration and lesion growth for the 
Symplicity Spyral and new-generation EnligHTN systems. A) Lesion 
depth versus time. B) Lesion width versus time. NGE: new-
generation EnligHTN; SS: Symplicity Spyral
Table 3. Lesion size and the percentage of growth at 20, 40 and 60 sec during radiofrequency ablation for Symplicity Spyral and 
new-generation EnligHTN.
Ablation 
time (sec)
Depth (mm)
p-value
Width (mm)
p-value
% Depth:width of maximum
SS NGE SS NGE SS NGE
20 1.52±0.03 1.87±0.02 <0.001 2.93±0.07 3.08±0.04 0.10 70.7:80.7 80.6:85.8
40 1.92±0.03 2.14±0.03 <0.001 3.45±0.08 3.44±0.04 0.86 89.3:95.0 92.2:95.8
60 2.15±0.02 2.32±0.02 <0.001 3.63±0.08 3.59±0.05 0.61 100:100 100:100
NGE: new-generation EnligHTN; SS: Symplicity Spyral
Discussion
Using the TLC renal artery phantom model, the NGE renal 
denervation system achieved greater lesion depth compared to the 
multi-electrode SS system. However, there was no difference in 
lesion width between the two systems. RF ablation with both sys-
tems was performed under consistent experimental settings (i.e., 
consistent gel impedance, gel temperature, vessel diameter and flow 
rate) and optimal electrode/gel contact as confirmed by direct visu-
alisation. Our phantom model allows direct comparison due to the 
ability to control variables, which is difficult to achieve clinically.
In our previous study, we compared the lesion dimensions 
and thermal properties of the single-electrode Symplicity Flex 
versus the first-generation multi-electrode EnligHTN renal 
artery denervation system, utilising the same renal artery phan-
tom model11. The present study is the first to compare the new-
generation multi-electrode Spyral system to the new-generation 
EnligHTN system using the TLC/gel phantom model. In RF abla-
tion, only about 1 mm of tissue adjacent to the electrode (area 
of resistive heating) is heated directly. Deeper tissue is heated by 
conduction of thermal energy from the resistive heating zone14.
Therefore, increased heating at the electrode tissue interface leads 
to more heat being conducted through the tissue and subsequently 
larger lesions. This is affected by several factors including ablation 
power, electrode size, electrode area in contact with tissue, contact 
force, convective cooling and ablation duration14,15. Whilst the SS 
electrode surface area is larger compared to the NGE (Table 1), 
lesions produced by the SS were comparatively smaller in depth. It 
has been demonstrated that increased electrode surface area results 
in larger lesions. Nonetheless, electrodes with a larger surface area 
usually require higher power delivery to maintain the same current 
density at the electrode tissue interface16-19. The maximum power 
generated by the SS and NGE is 6.5 W and 8 W, respectively. 
Conversely, a larger electrode area leads to more heat loss in the 
blood pool by convection and, therefore, reduces heating efficiency. 
Power lost in the blood pool is even greater when electrode-tissue 
contact is reduced15. It is possible that the greater contact force pro-
duced by the EnligHTN catheter upon deployment results in more 
optimal and stable gel contact, and therefore deeper lesions. It is 
important to note that for all ablations careful placement of the elec-
trode tip against the TLC/gel surface was consistent and confirmed. 
Haines demonstrated in an in vitro model that greater contact pres-
sure produced deeper lesions as long as electrode-tissue contact was 
maintained and electrode-tissue temperature kept constant by adjust-
ing power. In his study, lesion width showed no significant differ-
ence with increased contact force20. Consistent with this finding, we 
found no difference in width between the two systems. Although 
not directly measured, it is likely to be the design of the EnligHTN 
catheter that has the advantage of producing more consistent contact 
force. This could also explain the lower electrode tip temperature 
achieved by the SS (Table 2).
Of note, when the old-generation systems were used in the same 
model, the lesions produced were deeper (3.8 mm and 3.4 mm for 
Symplicity and EnligHTN, respectively)11. A recent animal study 
also suggested a thermal injury depth of 3.9 mm when the Symplicity 
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Flex was used21. Although the old- and the new-generation systems 
were not directly compared, the conditions of the phantom model 
were consistent between time points, suggesting a difference in per-
formance between the old- and the new-generation systems. In the 
case of the SS, a 50% reduction in ablation duration with lower power 
output compared to the old Symplicity system may have resulted in 
reduced net current density at the electrode-tissue interface despite 
the marginally smaller electrode surface area of this system. In addi-
tion, increased contact force at the tip of the Symplicity Flex catheter 
due to the ability to deflect the tip vector towards the gel interface 
could have produced a degree of contact force that minimised heat 
loss. For the NGE, smaller depth compared to the old EnligHTN 
system is probably partially due to shorter ablation duration.
Lesion size is one of several important elements for achieving 
clinical efficacy in RAD.  Deeper lesions may translate into more 
effective denervation, as more nerve bundles could be targeted. 
Clinically, successful denervation is important in order to achieve 
a significant BP reduction after RAD. Evidence from post-mor-
tem and animal studies has demonstrated that about 50% of renal 
nerves proximal to the bifurcation are located at a depth of greater 
than 2.44 mm22,23. Therefore, given the findings of the present 
study, ablation using the new-generation systems may potentially 
result in denervation of <50% of renal nerves at those sites, thus 
limiting the efficacy of the procedure. When assessing nerves at 
different vessel segments, it has been shown that most of the nerve 
bundles are located within the proximal and middle segments of 
the renal arteries. However, they are found at a greater depth in 
the proximal segment compared to the distal segment of the ves-
sel (3.4 mm proximally versus 2.6 mm distally), which renders 
the proximal nerve bundles more difficult to ablate endovascularly 
using the currently available denervation systems22. In distal seg-
ments (before the bifurcation), the 50th percentile of nerves was 
found to be at 1.81 mm from the lumen; 79% of nerves found dis-
tal to the bifurcation are located within 2 mm from the lumen22. 
The limited depth of heating and the current knowledge of renal 
nerve distribution highlight the importance of distal segment abla-
tion. This was demonstrated in a porcine model study by Mahfoud 
et al, where the addition of ablation distal to the bifurcation using 
the SS resulted in more effective denervation as measured by 
a reduction in cortical norepinephrine content and axonal density 
compared to main vessel ablation only24.
While the focus now has been directed towards more distal 
denervation (distal segment and distal to the bifurcation), improving 
ablation systems to reach deeper targets may also be beneficial, if 
this could be attained safely. Initial experimental studies using alter-
native energy modalities, including microwave ablation and chemi-
cal denervation, reported on lesion depth of 5-8 mm21,25. However, 
until additional research is conducted to evaluate the efficacy and 
safety of such modalities further, their use remains experimental.
Study limitations
Ablation conditions on the phantom renal artery model used in 
this study do not represent the complete spectrum of physiological 
conditions and acute response to RF ablation during renal denervation. 
In addition, the design of the current model allows assessment of 
heating pattern on a single plane only. Therefore, we were unable 
to assess heating of all four electrodes simultaneously, which may 
have an effect on heating pattern. However, the ability to control 
different variables and standardise the model allows us to compare 
the two systems under identical settings. Moreover, the effect of 
altering different parameters on lesion size could be assessed using 
this model in future studies. Lastly, we have chosen the 51°C iso-
therm to define lesion dimension. However, if nerve injury occurs at 
temperatures above or below this threshold, the actual depth of ther-
mal injury would be underestimated or overestimated. Nonetheless, 
for the application of RF ablation in neurosurgery it has been gen-
erally accepted that neural tissue destruction occurs at temperature 
≥45-50°C (lethal isotherm) and temperatures between 42-45°C 
showed reversible neural damage13,26.
Conclusions
Increased lesion depth was achieved using the NGE renal 
denervation system compared to the SS system for ablation on 
the TLC phantom model, with no difference in lesion width. 
Whilst the difference in depth is small, it may have an impact on 
denervation efficacy.
Impact on daily practice
The relationship between the renal nerves as a target for radio-
frequency ablation and ablation depth is one of several factors 
affecting denervation success. Information on different devices 
and technologies available with regard to their thermal proper-
ties and biophysics can guide clinicians as well as help us to 
understand the limitations of currently available systems and 
possible areas for improvement.
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